Cosmos Health Inc. announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement with Libytec Pharmaceutical S.A. for the production of the pharmaceutical product PathMuscle. Under the terms of the agreement, Cosmos Health will be responsible for the end-to-end manufacturing of PathMuscle, including formulation, production, quality control, and product release, in compliance with regulatory requirements. The contract includes firm minimum committed production volumes of 591,500 units and anticipates cumulative production volumes over a five-year period to exceed 1.2 million units, subject to market demand and commercial performance. PathMuscle will be distributed and commercially promoted in Greece by Libytec Pharmaceutical S.A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619768-en) on January 05, 2026, and is solely responsible for the information contained therein.